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Objective: To examine body mass index (BMI) and cognitive decline in subjects diagnosed with 
mild cognitive impairment (MCI). 
Methods:  Neuropsychological testing was conducted of 286 MCI subjects.  General estimating 
equations (GEE) assessed the relationships of baseline BMI with one-year change in global 
cognition. Logistic GEE assessed the relationship of BMI with a clinically significant decline in 
assessments of global cognition and conversion to Alzheimer’s disease (AD). 
Results:  Baseline BMI was associated with a significant decline in cognitive performance in 
MCI. We observed that a low baseline BMI as associated with an increased risk of a clinically 
significant decline in global cognition. No association between baseline BMI and conversion to 
AD was observed. 
Conclusions: Lower BMI is associated with a more rapid decline in cognition in MCI. This 
relationship suggests changes in metabolism are present in MCI or body composition may 
influence the rate of cognitive decline in MCI.   
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Introduction 
In 2006 there were 37.3 million individuals aged 65 or older living in the United States.  
This represents an increase of 10.0% in this age group within the last ten years. Additionally, the 
number of Americans aged 45-64 who will reach 65 over the next two decades is expected to 
increase by 39% during this decade.  As a result of this shifting demographic, by the year 2050 
the proportion of the total population with Alzheimer Disease (AD) will double (0.24%), 
compared to the 1995 population (0.14%).1 To address this growing concern, the Alzheimer's 
Disease Neuroimaging Initiative (ADNI) was launched in October 2004  to characterize the 
earliest clinical signs (imaging and biomarker) of the degenerative process that is likely to 
develop into AD.2, 3     
Some of the earliest characterizations of dementia have noted significant weight loss 
during the progression of the disease. 4-7 Weight loss is associated with more rapid  progression 
of AD and increased mortality.8 Interestingly, numerous studies have found weight loss to be 
associated with dementia many years prior to the emergence of clinically apparent symptoms.9-13  
In fact, atrophy of the brain in areas associated with feeding behavior have been found in AD 
subjects with low BMI. 14  Moreover, recent work in mouse models has shown that the obesity 
related hormone leptin is negatively related to the hallmark pathological process of AD.15 These 
studies are in contrast to previous works that have shown an association between midlife obesity 
the development of dementia.16-21  
To address this conflict, the primary focus of this study was to explore the relationship 
between BMI and cognitive decline. This study is unique in that it examines the role of BMI in 
subjects diagnosed with mild cognitive impairment (MCI). MCI is characterized as a transition 
phase between normal aging and Alzheimer disease (AD). Most individuals with the amnesic 
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form of MCI eventually develop AD, suggesting that, in many cases, MCI may be the earliest 
clinical phase of AD.22-24 While the diagnostic precision of MCI has been questioned,25 the 
clinical utility of MCI remains promising. Given that AD is a degenerative process, the rationale 
for this diagnostic construct is to identify individuals early in the disease process who would be 
most responsive to intervention. Our a priori hypothesis was that lower BMI would be 
associated with a more rapid decline in cognition in the MCI cohort.  
Methods 
Sample:  We compiled demographic, height, weight, and cognitive data on 286 MCI participants 
enrolled in ADNI. We restricted our analysis to subjects who had complete one-year follow up 
data as of the February 5th 2008.  ADNI criteria for MCI include an MMSE score between 24-30 
(inclusive), a memory complaint, have objective memory loss measured by education adjusted 
scores on Wechsler Memory Scale Logical Memory II, a clinical dementia rating (CDR) of 0.5, 
absence of significant levels of impairment in other cognitive domains, essentially preserved 
activities of daily living, and an absence of dementia. Baseline, 6 month, and 12-month 
psychometric and clinical data was collected from 286 individuals diagnosed with MCI. General 
estimating equations were used to assess the relationship between baseline BMI and one-year 
cognitive decline in the ADNI Cohort.   
Clinical Assessment: ADNI participants were evaluated with standard clinical and psychometric 
evaluations at baseline, 6-month and 12-months.  The  CDR 26 was performed at each follow up, 
a complete battery of clinical and neuropsychological measures were collected.  A standardized 
clinical evaluation was performed collecting information on demographics, vital signs including 
height and weight, concurrent medications, family history, physical exam, neurological exam, 
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and the Hachinski-ischemic score. BMI was calculated by dividing subject weight in kg by the 
square of the subject’s height in meters. Subjects were evaluated with the Hamilton Depression 
Rating Scale, Mini Mental State Examination, Alzheimer's Disease Assessment Scale-cognitive 
subscale (ADAS-Cog), WMS-R Logical Memory II, Auditory Verbal Learning Test, Boston 
Naming Test, Trail Making A & B, Digit Symbol, Clock Drawing Test, and Category Fluency. 
Following each clinical assessment, the evaluating clinician determines diagnostic conversion as 
well as a “clinically significant” worsening in the ADAS-Cog, MMSE, and the CDR sum of 
boxes assessments.  Per the ADNI protocol, the threshold for “clinically significant” is left to the 
judgment of the ADNI physician.  
Measures of Global Cognition:  
We used 4 measures to assess global cognitive performance: z-global, ADAS-Cog, the 
CDR sum of boxes, and MMSE.  
The MMSE is a screening instrument frequently used for Alzheimer’s disease drug 
studies. The scale evaluates orientation to place, orientation to time, registration (immediate 
repetition of three words), attention and concentration (serially subtracting seven beginning with 
100), recall (recalling the previously repeated three words), language (naming, repetition, 
reading, writing, comprehension), and visual construction (copy two intersecting pentagons). The 
MMSE measures cognitive impairment with a score ranging from 0 (best) to 30 (worst).27 
The ADAS-Cog is a structured scale that evaluates memory (word recall, word 
recognition), reasoning (following commands), language (naming, comprehension), orientation, 
ideational praxis (placing letter in envelope) and constructional praxis (copying geometric 
designs). Ratings of spoken language, language comprehension, word finding difficulty, and 
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ability to remember test instructions are also obtained. The test is scored in terms of errors, with 
higher scores reflecting poorer performance. Scores can range from 0 (best) to 70 (worse).28  
A global cognitive z-score was calculated for the following psychometric tests: (Logical 
Memory-Delayed Recall, Digit Span Forward: Total Correct, Digit Span Backward: Total 
Correct, Category fluency animals, Category fluency vegetables, Trail Making B,  Boston 
naming test, and Auditory Verbal Learning test, and Digit Score-Total Correct). The composite 
measure was derived as follows: 9 raw scores were transformed into z-scores utilizing the 
baseline means and standard deviations for each test calculated from baseline means and 
standard deviations from the cognitively normal subjects within the ADNI cohort. Subtest test z-
scores for participants with dementia were averaged to create a z-score for each cognitive test. If 
any of the individual test z-scores were missing, the global z-score was considered missing and 
was excluded from the analysis.  
The CDR describes five degrees of impairment in performance on each of 6 categories of 
cognitive functioning including memory, orientation, judgment and problem solving, community 
affairs, home and hobbies, and personal care. The ratings of degree of impairment obtained on 
each of the 6 categories of function are synthesized into one global rating of dementia (ranging 
from 0 to 3).26 
Statistical Analyses: To characterize baseline demographics, continuous variables were 
summarized by means and standard deviations while categorical variables were summarized by 
frequency and percent.  
In the longitudinal analysis, we explored the relationship between baseline BMI as a 
continuous variable and four global markers of cognitive decline, global z-score, MMSE, ADAS-
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Cog, CDR sum of boxes. Cognitive decline was modeled by linear generalized estimating 
equations (GEE) analyses as described by Twisk.29 Generalized estimating equations analysis is 
analogous to linear regression however, this analysis technique takes into account within-subject 
correlations found in longitudinal study designs. In the models tested, the dependent variables 
were the global z-score, ADAS-Cog, MMSE, and the CDR sum of boxes assessments. Predictor 
variables were baseline BMI, time, and a baseline BMI*time interaction. The interaction 
between baseline BMI and time modeled the influence of baseline BMI on the rate of cognitive 
decline.  
To examine the clinical significance of any association with cognitive decline and BMI, 
we modeled relationship between baseline BMI and the determination of a “clinically 
significant” decline in ADAS-Cog, MMSE, and CDR sum of boxes.  We used logistic 
generalized estimating equations to calculate odds ratios to assess the relationship between BMI 
and a “clinically significant” progression of MMSE, ADAS-Cog, and CDR box score.  
In this analysis, the presence or absence of a clinically significant cognitive decline was 
used as a dependent variable. Baseline BMI was fit as a continuous variable to estimate the 
likelihood of “clinically significant” cognitive worsening.  Similar logistic generalized 
estimating equations were used to assess the relationship between baseline BMI and the 
likelihood of progression from MCI to AD.  All predictive models controlled for age, gender, 
and education. We examined the within-subject correlation structure of the continuous outcome 
variables and determined that an exchangeable correlation structure would be the most 





Sample characteristics for the MCI cohort are outlined in Table 1. The MCI cohort had 
an average age of 75.0 (SD 7.5) and was 34% female mean baseline BMI of 26.0 (SD 4.0).  The 
cohort’s baseline mean MMSE was 26.9 (SD 1.8) and ADAS-Cog was 9.5 (SD 3.7).   
Relationship of BMI to Cognitive Performance  
General estimating equations were used in adjusted regression models to examine 
baseline BMI and its association with cognitive decline Table 2. Baseline BMI was not 
associated with any of the global tests of cognition.  Baseline BMI was associated with a reduced 
rate of cognitive decline in ADAS-cog, MMSE, global z-score. A one unit decrease in BMI at 
baseline was associated with a 1.3% decline in ADAS-cog performance (p=0.03), a 3.6% decline 
in MMSE score (p=<0.001), and a 3.5% decline (p=0.05) in global cognitive performance over a 
one year interval. No association was observed between CDR sum of boxes and baseline BMI. 
Figure 1 graphically represents the expected values of the prediction models and demonstrates 
the relationship between of baseline BMI and cognitive decline. To illustrate the magnitude of 
the influence of baseline BMI, the subject’s BMI was ranked into tertiles and plotted against 
time.  Subjects in the highest baseline BMI tertile show minimal cognitive decline whereas 
subjects in the lowest baseline BMI tertile had the most rapid decline.  
Baseline BMI and Clinically Significant Cognitive Decline  
To assess the clinical significance of the above findings logistic regression models were 
fit to estimate the odds of the determination of a subject’s clinically significant decline as 
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determined by the evaluating ADNI clinician, Table 2.  The event indicator in these models was 
coded as a clinically significantly worsening of the ADAS-Cog, MMSE, and the CDR Sum of 
Boxes.  We observed a protective effect of BMI in reducing the risk of ADAS-Cog decline 
(n=54, adjusted OR=0.91; CI 0.83-0.99; p=0.03) and a marginally significant protective effect in 
reducing MMSE decline (n=70, adjusted OR=0.93 CI 0.86-1.0; p=0.06). No association was 
found between BMI and CDR Box Score (n=86, adjusted OR=0.98 CI 0.91-1.05; p=0.54).  
Baseline BMI and Diagnostic Progression 
Over the one-year interval, we identified 54 subjects with MCI who converted to AD.  
Similar logistic regression models were fit to assess the relationship between BMI and clinical 
progression from MCI to AD, Table 3.  Baseline BMI was not found to be associated with the 
MCI cohort’s progression to AD (adjusted OR=0.98 CI 0.92-1.05; p=0.62). 
Discussion 
These results suggest a relationship between BMI and cognitive decline in MCI.  We 
observed that individuals with the lowest levels of BMI were associated with the highest levels 
of cognitive decline over a one-year interval.  Moreover, these results substantiate a clinical 
relevance of this finding. BMI was not found to be protective of diagnostic conversion to AD 
although only 52 participants converted to AD over the relatively short time frame of data 
analyzed.  This would suggest that a one-year analysis is sufficient to model the relationship 
between BMI and cognitive decline, but too short to model the relationship between BMI and the 
functional decline necessary for the progression from MCI to AD.  
These results confirm previous reports which suggest that alterations in body composition 
may occur months or years before the clinical symptoms of dementia.9, 10, 13, 30 These data imply 
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that age differentially modifies the association between BMI and cognitive decline and 
seemingly contrast reports that have shown that BMI in midlife represents a risk factor for the 
development of dementia.31-34  This phenomenon has been observed in other illnesses.  For 
instance, while BMI is a risk factor for cardiovascular disease and certain cancers, the link 
between obesity and all-cause mortality diminishes with increasing age and is greatly reduced or 
absent by the time individuals reach their mid-70s to early 80s.35 
While the mechanism of the weight loss in subjects with MCI is unknown, these findings 
raise questions about the mechanisms of the weight loss.  Body composition change may be 
related to behavioral changes such as reduced caloric intake due to forgetting to eat or the 
inability to plan and prepare adequate meals.  This issue, however, was addressed in previous 
work which showed that poor dietary intake alone can not explain weight loss in AD patients.36 
A physiologic mechanism may explain the association of BMI and cognitive decline in MCI. For 
instance, a higher BMI is associated with higher peripheral insulin which has been found to be 
associated with higher whole brain volume and better cognitive performance in the early-AD 
population.37 Atrophy of the mesial temporal cortex which is involved in feeding behavior and 
memory, has been shown to be associated with low BMI in AD patients.14 Finally, recent work 
as shown that increasing levels of obesity-related leptin negatively regulates Aβ levels in both 
mouse models and primary cultured neurons.15  
A major strength of this study is that the sample consisted of well-characterized MCI 
subjects that allowed us to explore the earliest stages of cognitive decline.  The strict diagnosis 
procedure minimizes the potential for misclassification bias that is common in many neruo-
cognitive studies.  Other strengths include the use of multiple cognitive assessments and the 
longitudinal nature of the study. Additionally, depressive symptoms have been shown to be 
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associated with weight changes in the elderly.38  Since depressed individuals were excluded from 
the ADNI study at baseline, this potential confounder did not affect these results.   
The primary limitation of the study was the short follow up. We cannot be sure if MCI 
subjects lost weight prior to diagnosis or if low BMI in MCI correlates with faster cognitive 
decline. Also, BMI does not differentiate between fat and muscle mass. Future studies should 
explore the use of more sophisticated measures of body composition to characterize the 
individual effects and distribution of lean mass and fat mass on cognitive decline. Finally, the 
MCI patients in the ADNI study were highly educated, non-depressed, community dwelling, and 
in good general health. These demographic characteristics may influence the generalizability of 
these results and may have influenced the true relationship of cognitive impairment with BMI in 
MCI. 
These findings indicate a negative association between BMI and cognitive decline in 
MCI. This suggests systemic alterations occurring some time prior to even the mildest cognitive 
disturbances. Low BMI or recent changes in BMI may be indicative of worse cognitive 
outcomes. Given these findings, one of two scenarios would seem plausible. First, low body 
weight may be a risk factor for the development of cognitive decline, as suggested by previous 
studies. 39  If so, these data suggest that elderly individuals may be responsive to exercise and 
dietary interventions designed to delay the onset of dementia.40 On the other hand, weight loss 
may be a down stream behavioral or neuro-biologic manifestation of AD related brain pathology. 
Indeed, there is now increasing evidence that AD related pathology may occur several years 
before clinical symptoms are present.41  If this is the case, weight loss may be one of the earliest 
clinical indicators of dementia in the elderly.  
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Table 1. Baseline Characteristics of MCI subjects   
Variable  
 
Mild Cognitive Impairment 
               n=286 
Demographics  
Age  75.0 (7.5) 
Female Gender n (%) 98 (34.1) 
Years of Education  15.8 (3.0) 




MMSE 26.9 (1.8) 
ADAS-Cog  9.5 (3.7) 
CDR Box Score 1.6 (0.9) 
Global Z-Score -0.97(0.6) 
 














Baseline BMI and “Clinically Significant” Cognitive Decline in MCI (n=286) 
 
Table 3. 









    
Assessment 







Effect Estimate  
(OR) 95% Confidence Interval P-value 
ADAS-Cog 54 0.91 0.83-0.99 0.03 
MMSE 70 0.93 0.86-1.0 0.06 
CDR Box 




Effect Estimate  
(OR) 95% Confidence Interval P-value 
52 0.98 0.92-1.05 0.62 
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Figure 1: 
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